AFP Antibody
Description
Biological Context of AFP
AFP is a 68.7 kDa glycoprotein belonging to the albuminoid family, encoded by a 609-amino acid gene (ALB/AFP/VDB family) . While crucial for immune regulation during gestation, its postnatal re-expression correlates with liver regeneration, hepatitis, and malignancies like HCC and germ cell tumors . Tumors producing AFP often exhibit aggressive features including poor differentiation and vascular invasion .
Structure and Function of AFP Antibodies
AFP antibodies are designed to recognize specific epitopes on the AFP protein. Key characteristics include:
Diagnostic and Research Applications
AFP antibodies are utilized in:
-
Immunohistochemistry: Localizing AFP in tissue samples to identify HCC or germ cell tumors .
-
ELISA/Western Blotting: Quantifying serum AFP levels for early cancer detection and monitoring .
-
Immunoprecipitation: Isolating AFP complexes to study protein interactions .
Elevated AFP levels (>20 ng/mL) indicate HCC recurrence risk and correlate with tumor size, differentiation status, and vascular invasion .
Therapeutic Development and Research Findings
Recent studies highlight AFP's dual role as both a diagnostic marker and immunotherapy target:
Vaccine Development
A peptide vaccine linking AFP epitopes to HSP70 functional peptides (HSP70-P/AFP-P) demonstrated:
-
26-fold increase in AFP-specific CD8+ T cells compared to controls .
-
12-fold elevation in granzyme B and perforin levels from natural killer cells .
-
Enhanced anti-AFP antibody production (10x higher than AFP-P alone) .
Table 1: Immunological outcomes in mice vaccinated with HSP70-P/AFP-P
| Parameter | PBS | AFP-P | HSP70-P | HSP70-P/AFP-P |
|---|---|---|---|---|
| IFN-γ+ CD8+ T cells | 17.35 | 18.32 | 17.74 | 478.65 |
| Granzyme B (pg/mL) | 8.47 | 8.37 | 8.49 | 104.73 |
| Perforin (pg/mL) | 7.78 | 8.25 | 8.38 | 97.78 |
| Anti-AFP Antibodies (μg/mL) | 1.40 | 1.41 | 1.43 | 14.76 |
Challenges and Future Directions
-
Low Immunogenicity: Native AFP vaccines often fail to induce robust immunity, necessitating adjuvants like HSP70 .
-
Tumor Microenvironment (TME) Interactions: AFP suppresses cytotoxic T cells and natural killer cells, complicating immunotherapy .
-
Biomarker Limitations: False positives occur in non-malignant liver diseases, requiring complementary markers like PIVKA-II .
Product Specs
Target Background
- Peak preoperative serum alpha-fetoprotein levels, relative to total tumor volume, are predictive of hepatocellular carcinoma recurrence. PMID: 29284589
- Research suggests that AFP may positively regulate cell proliferation by enhancing apoptosis resistance through its effects on TGF-beta and p53/Bax/caspase-3 signaling pathways in HepG2 cells. Consequently, the knockdown of the AFP gene warrants further investigation in vivo as a potential novel approach for hepatocellular carcinoma treatment. PMID: 30249880
- Aberrant CTNNB1 expression is observed in a significant proportion of hepatocellular carcinoma (HCC) cases. CTNNB1-positive HCC is associated with normal AFP levels, unicentric tumors, well-differentiated histology, and an unfavorable prognosis. PMID: 30082549
- Elevated preoperative serum alpha-fetoprotein levels hold predictive value for survival in patients with hepatocellular carcinoma. PMID: 28893428
- Cases of ovarian Sertoli-Leydig cell tumors (SLCTs) with elevated serum AFP should undergo extensive sampling to identify foci of intestinal-type glands, as these may be the source of the alpha-fetoprotein (AFP) elevation in some of these neoplasms. PMID: 28582340
- In HBV-related cirrhosis, the combination of miR-122, AFP, and PIVKA-II enables the identification of patients at an increased risk of hepatocellular carcinoma development. PMID: 28650134
- Longitudinal monitoring of AFP has significant predictive and prognostic value in managing advanced gastric cancer. Triple chemotherapy regimens may be a more suitable choice for patients with markedly elevated AFP levels. PMID: 29375212
- Low AFP expression is correlated with hepatocellular carcinoma recurrence. PMID: 29572833
- High PIVKA-II levels in at-risk individuals indicate a heightened risk of hepatocellular carcinoma (HCC) development within a two-year timeframe. Our findings suggest that PIVKA-II effectively enhances the detection rate of HCC and serves as a valuable complement to AFP and imaging examinations in HCC surveillance. PMID: 28863782
- Non-specific AFP elevations occur in approximately 2% of patients with pure testicular seminoma. PMID: 28668957
- Second trimester serum AFP levels are a significant indicator of fetal surface malformations. PMID: 27771626
- HCC [hepatocellular carcinoma] patients who are sero-positive for DCP [Des-gamma-carboxyprothrombin] and sero-negative for AFP [Alpha-fetoprotein] exhibit significantly higher levels of serum ALT [alanine aminotransferase]. Serum ALT levels may be diagnostically significant in AFP-negative, HBV-related HCC [hepatitis B virus-related hepatocellular carcinoma] patients. PMID: 29192630
- Higher baseline serum AFP levels independently predict a lower sustained viral response to antivirals among patients with chronic hepatitis C. PMID: 17713163
- Computer modeling identifies potential binding sites of lysophospholipids (LP) receptors on the AFP third domain receptor binding fragment. AFP might bind not only to the LPL receptors but also to LPLs themselves, as AFP binds medium and long-chain fatty acids. It is proposed that some of the activities attributed to AFP may be partially due to the presence of bound LPLs and/or their receptors. [review] PMID: 26844573
- AFP may be a crucial molecule that counteracts paclitaxel-inhibited proliferation and induced apoptosis in hepatocellular carcinoma cells by suppressing the activity of caspase-3 and stimulating the expression of Ras and Survivin. PMID: 27255186
- PIVKA II, when combined with AFP, can be considered a screening test for hepatocellular carcinoma due to its high negative predictive value. PMID: 28652441
- Identifying the distinct impact of circulating tumor-derived AFP on NK-cell function and viability is crucial for developing strategies to mitigate NK-cell functional deficits in hepatocellular carcinoma patients. PMID: 28468916
- The detection of ALT, AFP, AFP-L3, and GP73 provides valuable guidance for predicting the risk of hepatocellular carcinoma in patients with hepatic cirrhosis. PMID: 28540298
- Antibody therapy targeting AFP-producing tumor cells exhibits an inhibitory effect on the PI3K/AKT pathway by liberating, restoring, and functionally stabilizing PTEN. PTEN simultaneously induces both P53 activation and intracellular translocation of GLUT1, as these processes are closely associated with PTEN. PMID: 28498467
- Incorporating AFP status into the BCLC staging system to modify recommended treatment for patients with stage C hepatocellular carcinoma. PMID: 27835609
- Using alpha-fetoprotein (AFP), a specific liver cancer marker, as an example to determine whether peptide-MHC complexes can serve as targets for CAR T-cell therapy against solid tumors. In an established intraperitoneal liver cancer xenograft model, AFP-CAR T cells exhibited robust antitumor activity. PMID: 27535982
- miR-620, miR-1236, and miR-1270 are crucial factors in the post-transcriptional regulation of AFP in hepatitis B-infected hepatoma cells. Icaritin can counteract the effects of HBV. PMID: 27835879
- BWS registries and prospective clinical studies will assess the most effective methods for screening for hepatoblastoma, whether AFP-screened patients experience additional survival benefits compared to those screened by ultrasound alone, and if earlier detection improves outcomes. PMID: 28211991
- p55PIK significantly stimulates AFP expression by activating the NF-kappaB signaling pathway in hepatocellular carcinoma cells. PMID: 28970114
- An irregular MIP pattern on CEUS and high serum AFP-L3 levels are independent risk factors for poor outcomes following successful RFA. Patients with these findings should be considered a high-risk group for early-stage HCC. PMID: 27748052
- Our data suggests that HBeAg seroconversion and liver cirrhosis are associated with the development of HCC, and a surveillance system with regular AFP measurements to monitor for HCC may be essential for children and young adults with chronic HBV infection. PMID: 27748053
- Our cohort demonstrated the superior detection of early-stage HCC through the combined use of respective biomarkers, particularly GALAD, even in AFP-negative tumors. PMID: 27936479
- A correlation was observed between serum AFP concentration and age in extremely low-birthweight infants (ELBWI). The 95% CI of serum AFP concentration was determined for ELBWI up to 2 years after birth. PMID: 27400853
- rAFP promoted the growth of human HCC cells, antagonized paclitaxel inhibition of HCC cell proliferation, suppressed the expression of active caspase-3, and promoted the expression of Ras and survivin. PMID: 28554567
- Measurements of serum alpha-fetoprotein (AFP) levels may be helpful in detecting progression or recurrence in treated patients with hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) and normal alanine aminotransferase (ALT). PMID: 27304617
- AFP mRNA levels are enriched in circulating tumor cells from patients with metastatic hepatocellular carcinoma. PMID: 27160647
- High serum AFP levels were significantly associated with the prevalence of metabolic syndrome in a Chinese asymptomatic population. PMID: 27121855
- Contrary to expectations, chronic hepatitis B patients with current or recent exposure to nucleoside analog (NA) therapy exhibited poorer performance of AFP during hepatocellular carcinoma surveillance. PMID: 27997559
- Protein induced by vitamin K absence or antagonist-II demonstrated a higher area under the curve than alpha-fetoprotein for the diagnosis of hepatitis B virus-related hepatocellular carcinoma patients (0.901 vs 0.788). Combining alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II may improve the diagnostic value for early detection of hepatocellular carcinoma. PMID: 28621228
- AFP expression was activated prior to the expression of Oct4, Klf4, Sox2, and c-myc, as well as the stemness markers CD44, CD133, and EpCAM, in the normal human liver L-02 cell line or CHL cell lines upon transfection with MCV-HBx vectors. HBx stimulates AFP expression to induce natural reprogramming of liver cells, and AFP plays a critical role in promoting the initiation of HCC progenitor/stem cells. PMID: 27925189
- Analysis of alpha-fetoprotein producing early gastric cancer with enteroblastic differentiation. PMID: 27688662
- Lower post-treatment AFP levels and HCV genotype 2 significantly correlated with liver fibrosis regression after sustained virological response. PMID: 27123974
- Increased AFP expression resulted in upregulation of beta-catenin mRNA and protein levels, while knockdown of AFP with AFP shRNA led to significantly decreased beta-catenin mRNA and protein levels in hepatocellular carcinoma cells. PMID: 27924522
- Serum AFP levels differentiate hepatocellular carcinoma from liver cirrhosis, particularly when combined with acarboxyprothrombin. PMID: 28296720
- Soluble alpha-fetoprotein is a marker for Fanconi anemia; FANC proteins form multi-protein complexes with BRCA proteins and are involved in homologous DNA repair. [review] PMID: 27690720
- Studies indicate that the experimental data on the carboxy-terminal third domain of alpha-fetoprotein (AFP-3D) interaction with cell cycle proteins in cultured MCF-7 breast cancer cells were consistent with in silico findings. PMID: 27448301
- We evaluated the clinical performance of LOCItrade mark-based tumor marker assays CEA, CA19-9, CA15-3, CA125, and AFP in patients with gastrointestinal cancer and demonstrated their high diagnostic power. PMID: 28011514
- The definitive endoderm and foregut endoderm differentiation capabilities of Wnt pathway-modulated cells were determined based on the expression levels of the endodermal transcription factors SOX17 and FOXA2, and those of the transcription activator GATA4 and the alpha-fetoprotein (AFP) gene, respectively. PMID: 26861571
- Elevated serum AFP levels may have diagnostic value for early-stage hepatocellular carcinoma in Korean patients. PMID: 26767857
- AFP promoted hepatocellular carcinoma cell invasion and metastasis by upregulating the expression of metastasis-related proteins. PMID: 26756858
- Interference of AFP reduced AGS gastric cancer cell invasion and metastasis by enhancing anoikis sensitivity. PMID: 26986949
- High serum alpha-fetoprotein is associated with colon cancer. PMID: 26976278
- High serum AFP is associated with hepatitis B virus infection-related hepatocellular carcinoma. PMID: 26784252
- Elevated insulin resistance, leptin, serum iron, ferritin, mean platelet volume, NLR, and advanced fibrosis, as well as decreased platelet count and serum albumin, are independently associated with an elevated AFP level in chronic hepatitis C. PMID: 26618566
- VEGF could be a potential biomarker for HCC, while AFP could be used to distinguish between patients with HCC and cirrhosis or HCV. PMID: 26782388
Q&A
What is AFP and why are AFP antibodies important in research?
Alpha-fetoprotein is a 609-amino acid glycoprotein (68.7 kDa) secreted primarily during fetal development. It belongs to the ALB/AFP/VDB protein family and binds copper, nickel, and fatty acids . AFP antibodies are crucial research tools because:
-
They enable detection of this important biomarker in cancer research, particularly for hepatocellular carcinoma (HCC)
-
They facilitate the study of AFP's structure-function relationships
-
They provide means to investigate AFP's role in both normal development and disease states
AFP undergoes several post-translational modifications including protein cleavage, sulfation, and glycosylation, making its detection and characterization complex but valuable for understanding both normal physiology and pathological conditions .
What applications are AFP antibodies most commonly used for?
AFP antibodies support multiple research applications across different methodological platforms:
Research indicates that AFP antibodies coupled to magnetic nanoparticles in IMR assays achieve a detection threshold of 3 ng/mL, approximately 15 times lower than conventional ELISA methods .
How do different AFP antibodies compare in sensitivity and detection thresholds?
The sensitivity of AFP detection varies significantly between methodologies:
-
ELISA: Traditional method with detection threshold typically around 45 ng/mL
-
Immunomagnetic Reduction (IMR): Achieves 3 ng/mL detection threshold, offering superior sensitivity for early detection applications
-
Chemiluminescent Immunoassays: Single-step detection methods with variable sensitivity depending on antibody quality and measurement interference
For clinical research applications, the sensitivity/specificity trade-off is particularly important:
-
At 20 ng/mL cutoff: Sensitivity 41%-65%, Specificity 80%-94%
-
At 50 ng/mL cutoff: Sensitivity reduced to 47%, but Specificity increased to 96%
What are key considerations when selecting AFP antibodies for specific research applications?
Selection should be guided by:
-
Epitope specificity: Determine if your research requires detection of specific AFP domains or post-translational modifications
-
Cross-reactivity profile: Consider whether species cross-reactivity with mouse, rat, or other organisms is beneficial or problematic
-
Application compatibility: Some antibodies perform optimally in specific applications (WB vs. IHC vs. IF)
-
Conjugation requirements: Available options include unconjugated, HRP, PE, FITC, and Alexa Fluor® conjugates
-
Validation data: Review published literature demonstrating antibody performance in applications similar to your intended use
For example, antibody clone 189502 has been specifically validated for western blot and immunofluorescence applications with HepG2 human hepatocellular carcinoma cell lines .
What methodological considerations apply when using AFP antibodies for detecting different AFP isoforms?
AFP exists in multiple isoforms with distinct clinical significance. Methodology should be adapted accordingly:
-
Total AFP detection: Standard methods using antibodies against conserved AFP epitopes are suitable for general expression studies
-
AFP-L3 detection: This fucosylated isoform (Lens culinaris agglutinin-reactive fraction) is HCC-specific and requires specialized antibodies or lectin-based methods
-
Highly-sensitive AFP-L3 (hs-AFP-L3): Recent development showing improved sensitivity (84.9%) and specificity (88.6%) for early HCC detection
When investigating AFP-L3, researchers should consider:
-
Using lectin affinity fractionation before antibody detection
-
Employing antibodies specific to fucosylated epitopes
-
Establishing appropriate cutoff values (typically >10% of total AFP)
How can AFP antibodies be optimized for challenging samples or interference-prone environments?
Research samples frequently contain substances that may interfere with AFP detection. Optimization strategies include:
-
Sample pre-processing:
-
Removal of lipids and particulates through centrifugation
-
Dilution series to identify optimal sample concentration
-
Heat treatment protocols when appropriate
-
-
Interference mitigation:
Research has evaluated common interferents including:-
Hemoglobin (up to 500 mg/dL)
-
Conjugated bilirubin (up to 20 mg/dL)
-
Triglycerides (up to 3000 mg/dL)
IMR-based AFP detection showed minimal interference from these substances compared to ELISA methods .
-
-
Two-site antibody strategies:
What are emerging applications of AFP antibodies in cancer immunotherapy research?
AFP antibodies are playing important roles in developing novel cancer therapies:
-
CAR T-cell development:
-
AFP-specific chimeric antigen receptors (CARs) can be engineered to target AFP peptide-MHC complexes
-
Research has demonstrated that T cells expressing AFP-CAR can selectively target HLA-A*02:01+/AFP+ liver cancer cells
-
In vivo studies show significant tumor regression following intratumoral injection of AFP-CAR T cells in multiple xenograft models
-
-
AFP-targeted drug delivery:
-
AFP has specific receptors on certain cancer cells, making it promising for targeted drug delivery
-
Structural studies of AFP, facilitated by antibodies, are revealing binding sites for potential therapeutics
-
Understanding AFP's N-glycosylation patterns and binding characteristics is crucial for developing effective targeting strategies
-
How can researchers use AFP antibodies to study structural characteristics of AFP?
AFP's structure offers insights into its function and potential therapeutic applications:
-
Epitope mapping approaches:
-
Using panels of monoclonal antibodies targeting different domains
-
Domain-specific antibodies help characterize functional regions
-
-
Post-translational modification studies:
-
Binding site characterization:
-
Advanced structural analysis:
What validation protocols are recommended for AFP antibody research applications?
Rigorous validation ensures reliable research outcomes:
-
Positive controls:
-
Negative controls:
-
Adult healthy liver tissue (minimal AFP expression)
-
Cell lines known to lack AFP expression
-
Isotype-matched control antibodies
-
-
Specificity testing:
-
Reproducibility assessment:
-
Inter-assay and intra-assay coefficient of variation determination
-
Lot-to-lot consistency evaluation
-
Multiple detection methods cross-validation
-
What are the limitations of current AFP antibody-based detection methods?
Despite their utility, AFP antibody-based methods face several challenges:
-
Sensitivity and specificity trade-offs:
-
Interference factors:
-
Isoform differentiation:
-
Tumor size correlation limitations:
How can researchers improve AFP detection through multimarker approaches?
Combining AFP with other biomarkers significantly enhances diagnostic accuracy:
-
AFP + AFP-L3 + DCP (des-gamma-carboxyprothrombin):
-
GALAD score integration:
-
AFP + GP73 (Golgi protein 73):
-
MicroRNA combinations:
What emerging technologies may enhance AFP antibody applications?
Several innovative approaches are expanding AFP antibody utility:
-
Nanoparticle-based detection platforms:
-
Antibody engineering advances:
-
Fully human antibodies for therapeutic applications
-
Bispecific antibodies targeting AFP and additional tumor markers
-
-
Single-cell analysis techniques:
-
Combining AFP antibodies with single-cell sequencing
-
Mass cytometry for comprehensive profiling of AFP-expressing cells
-
-
In vivo imaging applications:
-
Radiolabeled AFP antibodies for tumor visualization
-
Photoacoustic imaging using AFP antibody-conjugated contrast agents
-
The continuing evolution of these technologies will expand the research applications of AFP antibodies beyond current limitations.
